Invesco
BTAI icon

Invesco’s BioXcel Therapeutics BTAI Stock Holding History

Invesco’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,178
Closed -$53.1K – 3885
2024
Q1 		$53.1K Buy
1,178
+294
+33% +$14K ﹤0.01% 3797
2023
Q4 		$41.7K Buy
+884
New +$49.1K ﹤0.01% 3760
2021
Q4 		– Sell
-463
Closed -$226K – 4037
2021
Q3 		$226K Buy
+463
New +$204K ﹤0.01% 3759
2020
Q3 		– Sell
-6,898
Closed -$5.85M – 3628
2020
Q2 		$5.85M Buy
+6,898
New +$4.5M ﹤0.01% 1912

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco's BTAI Position: Q2 2024 in Review

Invesco sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 1,178 shares — an estimated $53.1K sold.

Invesco first reported a position in BTAI in Q2 2020 and held it in 4 quarters. The position peaked at $5.85M in Q2 2020. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Invesco reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Invesco sold 1,178 BioXcel Therapeutics shares in Q2 2024, an estimated $53.1K.
  • Invesco first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 4 quarters.
  • Invesco's BioXcel Therapeutics position peaked at $5.85M in Q2 2020.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.